Sallysamir Zahran | Drug Development | Best Researcher Award

Published on by Scientist Day

Global Scientist Day Awards

Sallysamir Zahran
Affiliation Egyptian Atomic Energy Authority
Country Egypt
Scopus ID 56490517500
Documents 5
Citations 116
h-index 3
Subject Area Drug Development
Event Global Scientist Day Awards

Sallysamir Zahran

Institution: Egyptian Atomic Energy Authority
Country: Egypt

Sallysamir Zahran is associated with the Egyptian Atomic Energy Authority and contributes to scientific research in the interdisciplinary field of drug development. Research activities have focused on developing innovative pharmaceutical and biomedical solutions supported by experimental investigations and collaborative scientific approaches. Scholarly publications indexed in Scopus demonstrate sustained academic engagement and measurable citation impact within the international research community.[1]

Abstract

Drug development requires integration of pharmaceutical science, biomedical research, analytical methodologies, and translational innovation. Sallysamir Zahran’s scholarly work contributes to these objectives through research that supports improved therapeutic strategies and scientific understanding. The publication record indexed by Scopus reflects consistent scientific productivity, while citation metrics indicate that the research has been referenced by fellow investigators within related disciplines.[1]

Keywords

Drug Development, Pharmaceutical Sciences, Biomedical Research, Therapeutic Innovation, Drug Discovery, Translational Medicine, Experimental Pharmacology, Clinical Research, Medical Science, Scientific Publications

Introduction

Modern drug development combines chemistry, biology, pharmacology, toxicology, and clinical science to produce safe and effective therapeutic interventions. Researchers working within this multidisciplinary environment contribute to improving healthcare outcomes through systematic experimentation, validation, and scientific communication. Publications indexed by international databases such as Scopus provide evidence of research visibility and scholarly dissemination.[1]

Research Profile

Sallysamir Zahran is affiliated with the Egyptian Atomic Energy Authority and has established an academic profile within the field of drug development. According to the available Scopus author profile, the researcher has produced five indexed scholarly documents, accumulated 116 citations, and attained an h-index of 3. These indicators demonstrate measurable scientific engagement and continued participation in internationally indexed research activities.[1]

Research Contributions

The research contributions emphasize experimental investigations supporting pharmaceutical innovation and biomedical applications. Published studies contribute to scientific knowledge related to therapeutic development, laboratory evaluation, and evidence-based research methodologies. Collaborative investigations further strengthen interdisciplinary knowledge exchange while encouraging reproducibility and scientific transparency.[2]

Publications

Research publications indexed within Scopus demonstrate scholarly dissemination in drug development and associated biomedical sciences. These publications collectively contribute to scientific literature through experimental evidence and peer-reviewed communication. Representative research articles include publications with Digital Object Identifiers (DOIs), enabling persistent scholarly access.[2]

Research Impact

Citation-based indicators provide evidence that the published research has received attention from the broader scientific community. The available Scopus metrics indicate 116 citations across five indexed documents with an h-index of 3, reflecting measurable academic influence and continued relevance within drug development research.[1]

Award Suitability

Based on the available scholarly indicators, Sallysamir Zahran demonstrates characteristics commonly associated with academic recognition, including peer-reviewed publications, international indexing, measurable citation performance, and contributions to drug development research. The research portfolio aligns with the objectives of the Global Scientist Day Awards, which recognize scientific excellence, innovation, and continued advancement of research across diverse disciplines.[3]

Conclusion

Sallysamir Zahran has established a recognized research profile within the field of drug development through scholarly publications, citation impact, and international indexing. The documented research activities contribute to scientific knowledge while supporting continued innovation in pharmaceutical and biomedical sciences. The available academic record reflects meaningful participation in global research and represents a profile suitable for consideration within international scientific recognition programs.[1]

References

  1. Elsevier. (2026). Scopus Author Details: Sallysamir Zahran, Author ID 56490517500. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56490517500
  2. Novel pyrrole-sulfonamide derivatives as EGFR inhibitors and radiosensitizers in lung cancer.
    http://10.1016/j.bioorg.2025.109173
  3. Global Scientist Day Awards. (2026). Official Award Website.
    https://scientistday.org/

Ferenc Ötvös | Drug Development | Research Excellence Award

Published on by Scientist Day

Dr. Ferenc Ötvös | Drug Development | Research Excellence Award

Biological Research Centre | Szeged | Hungary

Dr. Ferenc Ötvös is a highly experienced chemist and senior research fellow with more than three decades of sustained contributions to molecular modelling, organic chemistry, and biomedical research. Currently serving at the HUN-REN Biological Centre in Szeged, Hungary, he has built a distinguished career characterized by methodological rigor, interdisciplinary collaboration, and innovation in drug discovery–oriented research. His scientific work demonstrates a strong integration of experimental chemistry with advanced computational approaches to enhance reliability, predictive power, and translational impact. Dr. Ötvös possesses specialist expertise in tritium labelling of existing and candidate drug molecules, particularly in the opioid research field, including the synthesis of complex precursors. His research portfolio also encompasses peptide design and synthesis, QSAR studies of opioid peptides, and the calculation of peptide–protein and protein–protein interactions using state-of-the-art docking methodologies. Notably, he has developed novel algorithmic approaches for docking to predict the pharmacological profiles of G-protein coupled receptor ligands, contributing significantly to structure–function understanding in molecular pharmacology. Beyond laboratory and computational research, Dr. Ötvös has played a pivotal role in advancing collaborative science. He has established strong international research networks, consulted with industry partners on practical applications of interaction energy calculations, and contributed to multiple interdisciplinary projects. His commitment to knowledge transfer is reflected in his teaching of advanced bioinformatics courses and in mentoring junior researchers through successful PhD completion. Earlier in his career, as a research assistant at the University of Szeged, Dr. Ötvös conducted IR spectroscopic studies of CO and CO₂ on supported noble metal catalysts and engaged in biochemical investigations of cardiac protein phospholamban, laying a strong foundation in both physical and biological chemistry. Dr. Ötvös holds a PhD in Organic Chemistry from the University of Szeged and is fluent in English. He is highly proficient in molecular modelling software, statistical analysis (R), and research design, and is widely recognized for his diligence, problem-solving ability, and excellence in grant proposal development and scholarly publishing.



View Orcid Profile

Featured Publications